How can we accelerate COVID-19 vaccine discovery?

Giulia Russo; Valentina Di Salvatore; Filippo Caraci; Cristina Curreli; Marco Viceconti; Francesco Pappalardo

doi:10.1080/17460441.2021.1935861

How can we accelerate COVID-19 vaccine discovery?

Expert Opin Drug Discov. 2021 Oct;16(10):1081-1084. doi: 10.1080/17460441.2021.1935861. Epub 2021 Jun 8.

Authors

Giulia Russo^{1

2}, Valentina Di Salvatore³, Filippo Caraci^{1

2}, Cristina Curreli^{4

5}, Marco Viceconti^{4

5}, Francesco Pappalardo¹

Affiliations

¹ Department of Drug and Health Sciences, University of Catania, Catania, Italy.
² Oasi Research Institute, IRCCS, Troina, Italy.
³ Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
⁴ Department of Industrial Engineering, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
⁵ Medical Technology Lab, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

No abstract available

Keywords: COVID-19; SARS-CoV-2 infection; in silico trials technologies; vaccine discovery.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Cheminformatics
Drug Discovery
Humans
SARS-CoV-2*

Substances

COVID-19 Vaccines

Grants and funding

The authors are funded by the STriTuVaD project. The STriTuVaD project has been funded by the European Commission and the Indian Department of Biotechnology, under the contract H2020-SC1-2017-CNECT-2, No. 777123.